Wall Street analysts expect Henry Schein, Inc. (NASDAQ:HSIC) to announce $2.35 billion in sales for the current quarter, according to Zacks. Seven analysts have issued estimates for Henry Schein’s earnings, with estimates ranging from $2.24 billion to $2.40 billion. Henry Schein reported sales of $3.22 billion during the same quarter last year, which would suggest a negative year over year growth rate of 27%. The firm is expected to report its next quarterly earnings report on Tuesday, May 14th.
According to Zacks, analysts expect that Henry Schein will report full year sales of $9.89 billion for the current financial year, with estimates ranging from $9.66 billion to $10.03 billion. For the next financial year, analysts anticipate that the firm will post sales of $10.39 billion, with estimates ranging from $10.16 billion to $10.54 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Henry Schein.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Wednesday, February 20th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.01. Henry Schein had a return on equity of 19.86% and a net margin of 4.06%. The business had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.46 billion. During the same quarter in the prior year, the firm earned $0.97 earnings per share. The business’s revenue was up 1.7% compared to the same quarter last year.
HSIC has been the subject of a number of research analyst reports. BidaskClub raised Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 27th. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a report on Wednesday, January 30th. ValuEngine lowered Henry Schein from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Craig Hallum dropped their price target on Henry Schein from $96.00 to $72.00 and set a “buy” rating for the company in a research report on Tuesday, February 19th. Finally, Royal Bank of Canada dropped their price target on Henry Schein to $62.00 and set a “sector perform” rating for the company in a research report on Thursday, February 21st. Seven equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $79.87.
Shares of Henry Schein stock traded up $0.19 during mid-day trading on Friday, reaching $59.29. 2,135,400 shares of the stock traded hands, compared to its average volume of 2,082,825. Henry Schein has a fifty-two week low of $56.58 and a fifty-two week high of $91.35. The stock has a market capitalization of $9.06 billion, a P/E ratio of 14.36, a PEG ratio of 2.22 and a beta of 0.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.30 and a quick ratio of 0.68.
Henry Schein announced that its board has initiated a share repurchase plan on Thursday, December 13th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to purchase up to 3.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.
In related news, Director Philip A. Laskawy sold 1,084 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $59.86, for a total value of $64,888.24. Following the completion of the transaction, the director now directly owns 32,899 shares in the company, valued at $1,969,334.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Philip A. Laskawy sold 3,591 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $59.12, for a total value of $212,299.92. The disclosure for this sale can be found here. 1.15% of the stock is owned by corporate insiders.
A number of institutional investors have recently modified their holdings of HSIC. Financial Gravity Companies Inc. purchased a new position in Henry Schein in the fourth quarter worth approximately $29,000. Bruderman Asset Management LLC purchased a new position in Henry Schein in the fourth quarter worth approximately $39,000. Ipswich Investment Management Co. Inc. purchased a new position in Henry Schein in the fourth quarter worth approximately $45,000. Howe & Rusling Inc. grew its position in Henry Schein by 200.0% in the fourth quarter. Howe & Rusling Inc. now owns 600 shares of the company’s stock worth $47,000 after acquiring an additional 400 shares during the period. Finally, Essex Savings Bank purchased a new position in Henry Schein in the fourth quarter worth approximately $48,000.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Story: Understanding Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.